Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Hara N, Ichihara E, Kano H, Ando C, Morita A, Nishi T, Okawa S, Nakasuka T, Hirabae A, Abe M, Asada N, Ninomiya K, Makimoto G, Fujii M, Kubo T, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Hara N, et al. Among authors: okawa s. Transl Lung Cancer Res. 2023 Oct 31;12(10):2098-2112. doi: 10.21037/tlcr-23-99. Epub 2023 Oct 26. Transl Lung Cancer Res. 2023. PMID: 38025818 Free PMC article.
Rapidly Progressive Multiple Cavity Formation in Necrotizing Pneumonia Caused by Community-acquired Methicillin-resistant Staphylococcus aureus Positive for the Panton-Valentine Leucocidin Gene.
Takigawa Y, Fujiwara K, Saito T, Nakasuka T, Ozeki T, Okawa S, Takada K, Iwamoto Y, Kayatani H, Minami D, Sato K, Nagao M, Shibayama T. Takigawa Y, et al. Among authors: okawa s. Intern Med. 2019 Mar 1;58(5):685-691. doi: 10.2169/internalmedicine.1454-18. Epub 2018 Oct 17. Intern Med. 2019. PMID: 30333405 Free PMC article.
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H, Ichihara E, Kayatani H, Makimoto G, Ninomiya K, Nishii K, Higo H, Ando C, Okawa S, Nakasuka T, Kano H, Hara N, Hirabae A, Kato Y, Ninomiya T, Kubo T, Rai K, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Watanabe H, et al. Among authors: okawa s. Cancer Sci. 2021 May;112(5):1853-1864. doi: 10.1111/cas.14801. Epub 2021 Mar 18. Cancer Sci. 2021. PMID: 33410241 Free PMC article.
A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide.
Kawamura S, Kubo T, Takada K, Sunami R, Okawa S, Iwamoto Y, Hirabae A, Taniguchi A, Maeda Y, Kiura K, Tabata M. Kawamura S, et al. Among authors: okawa s. Int Cancer Conf J. 2021 Mar 16;10(3):197-200. doi: 10.1007/s13691-021-00475-1. eCollection 2021 Jul. Int Cancer Conf J. 2021. PMID: 34221831 Free PMC article.
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I.
Brägelmann J, Lorenz C, Borchmann S, Nishii K, Wegner J, Meder L, Ostendorp J, Ast DF, Heimsoeth A, Nakasuka T, Hirabae A, Okawa S, Dammert MA, Plenker D, Klein S, Lohneis P, Gu J, Godfrey LK, Forster J, Trajkovic-Arsic M, Zillinger T, Haarmann M, Quaas A, Lennartz S, Schmiel M, D'Rozario J, Thomas ES, Li H, Schmitt CA, George J, Thomas RK, von Karstedt S, Hartmann G, Büttner R, Ullrich RT, Siveke JT, Ohashi K, Schlee M, Sos ML. Brägelmann J, et al. Among authors: okawa s. Nat Commun. 2021 Sep 17;12(1):5505. doi: 10.1038/s41467-021-25728-8. Nat Commun. 2021. PMID: 34535668 Free PMC article.
Identification of targetable kinases in idiopathic pulmonary fibrosis.
Higo H, Ohashi K, Tomida S, Okawa S, Yamamoto H, Sugimoto S, Senoo S, Makimoto G, Ninomiya K, Nakasuka T, Nishii K, Taniguchi A, Kubo T, Ichihara E, Hotta K, Miyahara N, Maeda Y, Toyooka S, Kiura K. Higo H, et al. Among authors: okawa s. Respir Res. 2022 Feb 7;23(1):20. doi: 10.1186/s12931-022-01940-y. Respir Res. 2022. PMID: 35130915 Free PMC article.
CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer.
Nishii K, Ohashi K, Tomida S, Nakasuka T, Hirabae A, Okawa S, Nishimura J, Higo H, Watanabe H, Kano H, Ando C, Makimoto G, Ninomiya K, Kato Y, Kubo T, Ichihara E, Hotta K, Tabata M, Toyooka S, Udono H, Maeda Y, Kiura K. Nishii K, et al. Among authors: okawa s. Cancer Immunol Res. 2022 Sep 1;10(9):1111-1126. doi: 10.1158/2326-6066.CIR-21-0751. Cancer Immunol Res. 2022. PMID: 35802887 Free article.
PD-1 blockade augments CD8+ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancer.
Nakasuka T, Ohashi K, Nishii K, Hirabae A, Okawa S, Tomonobu N, Takada K, Ando C, Watanabe H, Makimoto G, Ninomiya K, Fujii M, Kubo T, Ichihara E, Hotta K, Tabata M, Kumon H, Maeda Y, Kiura K. Nakasuka T, et al. Among authors: okawa s. Lung Cancer. 2023 Apr;178:1-10. doi: 10.1016/j.lungcan.2023.01.018. Epub 2023 Feb 1. Lung Cancer. 2023. PMID: 36753780
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
Kuribayashi T, Ohashi K, Nishii K, Ninomiya K, Tsubata Y, Ishikawa N, Kodani M, Kanaji N, Yamasaki M, Fujitaka K, Kuyama S, Takigawa N, Fujimoto N, Kubota T, Inoue M, Fujiwara K, Harita S, Takata I, Takada K, Okawa S, Kiura K, Hotta K. Kuribayashi T, et al. Among authors: okawa s. J Cancer Res Clin Oncol. 2024 Feb 12;150(2):89. doi: 10.1007/s00432-024-05618-4. J Cancer Res Clin Oncol. 2024. PMID: 38347279 Free PMC article.
296 results